Grazia Vivanet

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls

C. Criscitiello, G. Curigliano, G. Bonizzi, 2022, Cancer drug resistance.

High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study.

G. Curigliano, Z. Ballatore, R. Berardi, 2023, Lung cancer.

Evolution of low HER2 expression between early and advanced-stage breast cancer.

C. Criscitiello, G. Curigliano, S. Gandini, 2022, European journal of cancer.

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

C. Criscitiello, G. Curigliano, A. Friedlaender, 2021, Cancers.

SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis

G. Curigliano, P. Queirolo, Z. Ballatore, 2022, European Journal of Cancer.

Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.

C. Criscitiello, G. Curigliano, A. Friedlaender, 2023, European journal of cancer.